Neuropace Inc (NPCE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $260.45M
Last updated: Nov 17, 2026 at 4:30 PM ET
Neuropace Inc (NPCE) Statistics
Neuropace (NPCE) has a market cap of $260.45M and an enterprise value of $309.38M. It kept -20.00% of revenue as net income over the last 12 months. Its share count is up 3.66% from a year earlier.
Total Valuation
Enterprise value is 18.78% above the market cap, as debt exceeds cash.
| Market Cap | $260.45M |
|---|---|
| Enterprise Value | $309.38M |
| Latest price (Nov 17, 2026) | $8.20 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.0x and 24.5x. Its year-end P/S ranged from 0.2x to 5.5x from 2021 to 2025.
| P/S Ratio | 3.0x |
|---|---|
| Forward P/S | 2.9x |
| P/B Ratio | 24.5x |
Price Statistics
The stock is down 36.63% over 52 weeks and trades 36.63% below its 50-day average.
| Beta (1Y) | 1.35 |
|---|---|
| 52-Week Change | -36.63% |
| 1-Month Change | -35.79% |
| 3-Month Change | -43.99% |
| 6-Month Change | -48.27% |
| 5-Year Change | -18.87% |
| Total Return (1Y) | -36.63% |
| Total Return (3Y CAGR) | -1.76% |
| Total Return (5Y CAGR) | -6.45% |
| Return vs SPY (1Y) | -48.58% |
| Max Drawdown (1Y) | -60.81% |
| Max Drawdown (3Y) | -66.29% |
| Sharpe Ratio (1Y) | -0.67 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $12.94 |
| 200-Day Average | $14.69 |
| 52-Week Range | $5.46 to $19.60 |
| RSI (14 Days) | 26.5 |
| Average Volume (20 Days) | 535.05K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.26x current liabilities, and total debt is 5.15x shareholder equity.
| Current Ratio | 5.26x |
|---|---|
| Quick Ratio | 4.09x |
| Debt / Equity | 5.15x |
| Interest Coverage | -2.40x |
Returns and Efficiency
Return on invested capital is -16.69% over the last 12 months, against a 5-year average of -17.06%.
| Return on Equity (ROE) | -164.60% |
|---|---|
| Return on Assets (ROA) | -19.96% |
| Return on Invested Capital (ROIC) | -16.69% |
| Return on Capital Employed (ROCE) | -18.97% |
| ROA (5Y Average) | -29.58% |
| ROIC (5Y Average) | -17.06% |
| Asset Turnover | 0.94x |
| Inventory Turnover | 0.95x |
| Receivables Turnover | 6.48x |
| Cash Conversion Cycle | 362 days |
Scores
NPCE has an Altman Z-Score of -5.03, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.03 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $94.59M over the last 12 months is up 8.92% from the 12 months before.
| Revenue | $94.59M |
|---|---|
| Revenue Growth (YoY) | +8.92% |
| Gross Profit | $77.00M |
| Operating Income | -$14.56M |
| Pretax Income | -$18.92M |
| Net Income | -$18.92M |
| EBITDA | -$12.54M |
| EBIT | -$14.93M |
| Reported EPS (TTM) | -$0.56 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 12.12% of the $94.78M in total assets.
| Cash and Equivalents | $10.23M |
|---|---|
| Total Debt | $59.16M |
| Net Debt | $48.92M |
| Net Debt Per Share | $1.42 |
| Working Capital | $68.47M |
| Shareholder Equity | $11.49M |
| Book Value Per Share | $0.33 |
| Total Assets | $94.78M |
| Total Liabilities | $83.28M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $355.00K of capital spending, operating cash flow left -$12.41M of free cash flow.
| Operating Cash Flow | -$12.06M |
|---|---|
| Capital Expenditures | $355.00K |
| Free Cash Flow | -$12.41M |
| FCF Per Share | -$0.36 |
| Depreciation and Amortization | $2.39M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -15.39%, against a 5-year average of -45.43%.
| Gross Margin | 81.41% |
|---|---|
| Operating Margin | -15.39% |
| Pretax Margin | -20.00% |
| Net Margin | -20.00% |
| EBITDA Margin | -13.25% |
| EBIT Margin | -15.78% |
| FCF Margin | -13.13% |
| Gross Margin (5Y Average) | 74.02% |
| Operating Margin (5Y Average) | -45.43% |
| Net Margin (5Y Average) | -57.82% |
Growth
Revenue grew 29.99% a year over 3 years.
| Revenue Growth (3Y CAGR) | +29.99% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.44% |
| Book Value Per Share Growth (2Y CAGR) | -14.54% |
| Tangible Book Per Share Growth (2Y CAGR) | -14.54% |
Dividends and Yields
NPCE does not pay a dividend. Its free cash flow yield is -4.41%.
| FCF Yield | -4.41% |
|---|---|
| Buyback Yield | -0.94% |
| Shareholder Yield | -0.94% |
Peer Position
Against 12 similar companies, NPCE has the 5th highest P/S.
P/S RatioPeer median 1.6x
ROICPeer median -21.12%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.10%
| P/S Ratio | 3.0x vs 1.6x median |
|---|---|
| ROIC | -16.69% vs -21.12% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.92% vs +14.10% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.56% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.56% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NPCE
What is NPCE's market cap?
Neuropace has a market cap of $260.45M. Its enterprise value, which adds debt and subtracts cash, is $309.38M.
How many shares of NPCE are outstanding?
Neuropace has 34.35M shares outstanding. The count is up 3.66% from a year earlier.
Does NPCE pay a dividend?
No. Neuropace does not pay a dividend.
How much debt does NPCE have?
Neuropace has $59.16M of total debt and $10.23M of cash and equivalents, a net debt position of $48.92M.
NPCE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts